Blood Res.
2019 Mar;54(1):77-79. 10.5045/br.2019.54.1.77.
Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
- Affiliations
-
- 1Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, Korea. xuno@cau.ac.kr
- 2Department of Laboratory Medicine, Chung-Ang University, Seoul, Korea.
- KMID: 2451060
- DOI: http://doi.org/10.5045/br.2019.54.1.77
Abstract
- No abstract available.
MeSH Terms
Cited by 1 articles
-
Clinical significance of myeloproliferative neoplasms with
JAK2 V617F mutations and majorBCR-ABL1 translocations: a literature review with case presentation
Bohyun Kim, Kyu Taek Lee, Young Ahn Yoon, Young-Jin Choi
Blood Res. 2020;55(1):62-65. doi: 10.5045/br.2020.55.1.62.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Acute Myeloid Leukemia Transformed from JAK2 V617F-Positive Chronic Neutrophilic Leukemia
- JAK2V617F-Positive Acute Myeloid Leukemia: Clinicopathological Features of Two Cases
- Dasatinib (Sprycel®)-Associated Acneiform Eruption Improved by Dose Reduction due to Pleural Effusion in a Patient with Chronic Myeloid Leukemia
- A Pediatric Case of Atypical Chronic Myeloid Leukemia with CSF3R Mutation Not Responding to Ruxolitinib, but Rescued by Allogeneic Transplantation
- Depigmentation in a Patient with Chronic Myeloid Leukemia during Chemotherapy with Dasatinib
